Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

A Phase 3 Multicenter, Open-Label Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826-83) 20 mg or 80 mg (or Tafamidis [PF-06291826-00] 61 mg) in Subjects Diagnosed With Transthyretin Cardiomyopathy (ATTR-CM)